Ignacio Conget
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ignacio Conget has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
- Marga Giménez
Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (FCRB-IDIBAPS), 08036 Barcelona, Spain
20 shared publications R. Casamitjana
IDIBAPS (Institut d’Investigacions Biomèdicas August Pi i Sunyer), Hospital Clínic i Universitari
5 shared publicationsRoser Casamitjana
Hormonal Unit, Hospital Clínic, Barcelona, Spain
5 shared publicationsIrene Vinagre
Diabetes Unit, Endocrinology and Nutrition Dpt. Hospital Clínic, Barcelona, Spain
4 shared publicationsAngels Costa
From the Diabetes Unit, Endocrinology Department, IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer); CIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM); Hospital Clínic i Universitari, Barcelona, Spain
3 shared publications- Antonio Jesús Amor
Diabetes Unit, Endocrinology and Nutrition Department, Hospital Clínic, Barcelona, Spain
3 shared publications
Latest Publications
- 1 April 2020
- Published by Elsevier in Primary Care Diabetes
- Vol. 14 (2) , 168-172
Frequency and awareness of hypoglycemia in patients with Type 2 Diabetes treated with two or more insulin injections in primary care outpatient clinics
- 1 April 2020
- Published by Elsevier in Primary Care Diabetes
- Vol. 14 (2) , 168-172
Frequency and awareness of hypoglycemia in patients with Type 2 Diabetes treated with two or more insulin injections in primary care outpatient clinics
- 1 February 2019
- Published by Elsevier in Endocrinología, Diabetes y Nutrición
- Vol. 66 (2) , 117-123
Experiences and real life management of insulin pump therapy in adults with type 1 diabetes
- 1 February 2019
- Published by Elsevier in Endocrinología, Diabetes y Nutrición
- Vol. 66 (2) , 117-123
Experiences and real life management of insulin pump therapy in adults with type 1 diabetes
- 24 November 2017
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 34 (2) , 329-336
Identifying insulin treatment responders with a composite measure: beyond Hba1c < 7% in patients with type 2 diabetes
Objectives: Many insulin-treated patients with type 2 diabetes (T2D) do not reach hemoglobin A1c (HbA1c) < 7%, but have clinically relevant HbA1c reductions. Using an integrated database (IDB) of 53 insulin lispro clinical trials and a real-world evidence (RWE) database of T2D patients initiating insulin therapy, an expanded HbA1c measure was used to identify responders to insulin therapy. Methods: Analysis included 4,908 patients (IDB) and 1,134 patients (RWE) with T2D treated with any insulin regimen with a baseline and ≥1 post-baseline HbA1c. Responders were defined as patients with endpoint HbA1c < 7% (cut point [CP]) and/or either ≥1% absolute (ABS) decrease, and/or ≥10% relative (REL) decrease in HbA1c from baseline. The percentage of responders with CP vs ABS and concordance between ABS and REL were calculated. As the ABS and REL measures were highly correlated (94%), the ABS measure was used to compare characteristics of responders and non-responders by age, diabetes duration, race/ethnicity, baseline HbA1c, and insulin regimen at 24 weeks. Results: In both databases, more responders were identified with ABS or REL (>62%) than CP (<41%). More ABS responders had a baseline HbA1c ≥ 9% and a shorter diabetes duration than non-responders. Basal insulin-treated patients in the IDB had 78.2% responders at 24 weeks, compared to 69.7% with basal/bolus or pre-mixed insulin (75.4%). Results were similar in the IDB and RWE. Conclusion: Composite HbA1c measures identified more patients with clinically meaningful responses to therapy than the broadly accepted HbA1c < 7% and may be useful in assessing clinical trials, clinical care, and quality measures.
- 24 November 2017
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 34 (2) , 329-336
Identifying insulin treatment responders with a composite measure: beyond Hba1c < 7% in patients with type 2 diabetes
Objectives: Many insulin-treated patients with type 2 diabetes (T2D) do not reach hemoglobin A1c (HbA1c) < 7%, but have clinically relevant HbA1c reductions. Using an integrated database (IDB) of 53 insulin lispro clinical trials and a real-world evidence (RWE) database of T2D patients initiating insulin therapy, an expanded HbA1c measure was used to identify responders to insulin therapy. Methods: Analysis included 4,908 patients (IDB) and 1,134 patients (RWE) with T2D treated with any insulin regimen with a baseline and ≥1 post-baseline HbA1c. Responders were defined as patients with endpoint HbA1c < 7% (cut point [CP]) and/or either ≥1% absolute (ABS) decrease, and/or ≥10% relative (REL) decrease in HbA1c from baseline. The percentage of responders with CP vs ABS and concordance between ABS and REL were calculated. As the ABS and REL measures were highly correlated (94%), the ABS measure was used to compare characteristics of responders and non-responders by age, diabetes duration, race/ethnicity, baseline HbA1c, and insulin regimen at 24 weeks. Results: In both databases, more responders were identified with ABS or REL (>62%) than CP (<41%). More ABS responders had a baseline HbA1c ≥ 9% and a shorter diabetes duration than non-responders. Basal insulin-treated patients in the IDB had 78.2% responders at 24 weeks, compared to 69.7% with basal/bolus or pre-mixed insulin (75.4%). Results were similar in the IDB and RWE. Conclusion: Composite HbA1c measures identified more patients with clinically meaningful responses to therapy than the broadly accepted HbA1c < 7% and may be useful in assessing clinical trials, clinical care, and quality measures.
- 1 August 2017
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 19 (8) , 491-492
Severe Hypoglycemia Before Landing in a Patient with Type 1 Diabetes Using Sensor-Augmented Pump Therapy
- 1 August 2017
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 19 (8) , 491-492
Severe Hypoglycemia Before Landing in a Patient with Type 1 Diabetes Using Sensor-Augmented Pump Therapy
- 1 August 2016
- Published by Elsevier in Endocrinología y Nutrición
- Vol. 63 (7) , 339-344
Clinical status of a cohort of patients with type 1 diabetes diagnosed more than 2 decades before. Results of a specific clinical follow-up program
- 1 August 2016
- Published by Elsevier in Endocrinología y Nutrición
- Vol. 63 (7) , 339-344
Clinical status of a cohort of patients with type 1 diabetes diagnosed more than 2 decades before. Results of a specific clinical follow-up program
- 1 July 2016
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 18 (7) , 448
Response to Letter to the Editor Regarding OpT2mise Study
- 1 July 2016
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 18 (7) , 448
Response to Letter to the Editor Regarding OpT2mise Study
- 1 March 2016
- Published by Elsevier in Endocrinología y Nutrición
- Vol. 63 (3) , 121-125
Impaired awareness of hypoglycaemia in subjects with type 1 diabetes. Results of an online survey in a diabetes web site
- 1 March 2016
- Published by Elsevier in Endocrinología y Nutrición
- Vol. 63 (3) , 121-125
Impaired awareness of hypoglycaemia in subjects with type 1 diabetes. Results of an online survey in a diabetes web site
- Open Access
- 1 January 2016
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 18 (1) , 22-28
The Impact of Insulin Pump Therapy on Glycemic Profiles in Patients with Type 2 Diabetes: Data from the OpT2mise Study
Background: The OpT2mise randomized trial was designed to compare the effects of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) on glucose profiles in patients with type 2 diabetes. Research Design and Methods: Patients with glycated hemoglobin (HbA 1c ) levels of ≥8% (64 mmol/mol) and ≤12% (108 mmol/mol) despite insulin doses of 0.7–1.8 U/kg/day via MDI were randomized to CSII ( n =168) or continued MDI ( n =163). Changes in glucose profiles were evaluated using continuous glucose monitoring data collected over 6-day periods before and 6 months after randomization. Results: After 6 months, reductions in HbA 1c levels were significantly greater with CSII (−1.1±1.2% [−12.0±13.1 mmol/mol]) than with MDI (−0.4±1.1% [−4.4±12.0 mmol/mol]) ( P 180 mg/dL (−12.4%; P =0.0004) and SG >250 mg/dL (−5.5%; P =0.0153), and more time in the SG range of 70–180 mg/dL (12.3%; P =0.0002), with no differences in exposure to SG180 mg/dL were significantly greater with CSII than with MDI after breakfast (−775.9±1,441.2 mg/dL/min vs. −160.7±1,074.1 mg/dL/min; P =0.0015) and after dinner (−731.4±1,580.7 mg/dL/min vs. −71.1±1,083.5 mg/dL/min; P =0.0014). Conclusions: In patients with suboptimally controlled type 2 diabetes, CSII significantly improves selected glucometrics, compared with MDI, without increasing the risk of hypoglycemia.
- 1 January 2016
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 18 (1) , 22-28
Open AccessThe Impact of Insulin Pump Therapy on Glycemic Profiles in Patients with Type 2 Diabetes: Data from the OpT2mise Study
Background: The OpT2mise randomized trial was designed to compare the effects of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) on glucose profiles in patients with type 2 diabetes. Research Design and Methods: Patients with glycated hemoglobin (HbA 1c ) levels of ≥8% (64 mmol/mol) and ≤12% (108 mmol/mol) despite insulin doses of 0.7–1.8 U/kg/day via MDI were randomized to CSII ( n =168) or continued MDI ( n =163). Changes in glucose profiles were evaluated using continuous glucose monitoring data collected over 6-day periods before and 6 months after randomization. Results: After 6 months, reductions in HbA 1c levels were significantly greater with CSII (−1.1±1.2% [−12.0±13.1 mmol/mol]) than with MDI (−0.4±1.1% [−4.4±12.0 mmol/mol]) ( P 180 mg/dL (−12.4%; P =0.0004) and SG >250 mg/dL (−5.5%; P =0.0153), and more time in the SG range of 70–180 mg/dL (12.3%; P =0.0002), with no differences in exposure to SG180 mg/dL were significantly greater with CSII than with MDI after breakfast (−775.9±1,441.2 mg/dL/min vs. −160.7±1,074.1 mg/dL/min; P =0.0015) and after dinner (−731.4±1,580.7 mg/dL/min vs. −71.1±1,083.5 mg/dL/min; P =0.0014). Conclusions: In patients with suboptimally controlled type 2 diabetes, CSII significantly improves selected glucometrics, compared with MDI, without increasing the risk of hypoglycemia.